Please use this identifier to cite or link to this item:
https://doi.org/10.1038/leu.2016.186
Title: | Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study | Authors: | Moreau, P Joshua, D Chng, W-J Palumbo, A Goldschmidt, H Hajek, R Facon, T Ludwig, H Pour, L Niesvizky, R Oriol, A Rosinol, L Suvorov, A Gaidano, G Pika, T Weisel, K Goranova-Marinova, V Gillenwater, HH Mohamed, N Aggarwal, S Feng, S Dimopoulos, MA |
Keywords: | Science & Technology Life Sciences & Biomedicine Oncology Hematology STEM-CELL TRANSPLANTATION LENALIDOMIDE MAINTENANCE RETREATMENT INHIBITOR |
Issue Date: | 1-Jan-2017 | Publisher: | NATURE PUBLISHING GROUP | Citation: | Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA (2017-01-01). Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. LEUKEMIA 31 (1) : 115-122. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2016.186 | Abstract: | The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ≥2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (≥2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide. | Source Title: | LEUKEMIA | URI: | https://scholarbank.nus.edu.sg/handle/10635/229017 | ISSN: | 08876924 14765551 |
DOI: | 10.1038/leu.2016.186 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomi.pdf | Published version | 365.64 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.